A detailed history of Creative Planning transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Creative Planning holds 18,973 shares of SMMT stock, worth $344,929. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,973
Previous 15,633 21.37%
Holding current value
$344,929
Previous $342,000 1.17%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$17.52 - $23.46 $58,516 - $78,356
3,340 Added 21.37%
18,973 $338,000
Q3 2024

Oct 11, 2024

BUY
$6.89 - $31.93 $33,423 - $154,892
4,851 Added 44.99%
15,633 $342,000
Q2 2024

Aug 15, 2024

BUY
$2.39 - $10.92 $25,768 - $117,739
10,782 New
10,782 $84,000
Q2 2023

Jul 21, 2023

BUY
$1.32 - $2.81 $5,045 - $10,739
3,822 Added 30.31%
16,430 $41,000
Q1 2023

May 15, 2023

BUY
$1.38 - $5.41 $17,399 - $68,209
12,608 New
12,608 $22,000

Others Institutions Holding SMMT

About Summit Therapeutics Inc.


  • Ticker SMMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 201,215,008
  • Market Cap $3.66B
  • Description
  • Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...
More about SMMT
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.